214 related articles for article (PubMed ID: 7996419)
1. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.
Silver PJ; Pagani ED; Dundore RL; de Garavilla L; Bode DC; Bacon ER
Eur J Pharmacol; 1998 May; 349(2-3):263-8. PubMed ID: 9671106
[TBL] [Abstract][Full Text] [Related]
4. Impaired effect of salt loading on nitric oxide-mediated relaxation in aortas from stroke-prone spontaneously hypertensive rats.
Kagota S; Kubota Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
Clin Exp Pharmacol Physiol; 2007; 34(1-2):48-54. PubMed ID: 17201735
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of low Km cGMP phosphodiesterases and Ca+(+)-regulated protein kinases and relationship to vasorelaxation by cicletanine.
Silver PJ; O'Connor B; Cumiskey WR; Van Aller G; Hamel LT; Bentley RG; Pagani ED
J Pharmacol Exp Ther; 1991 Apr; 257(1):382-91. PubMed ID: 1850474
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
[TBL] [Abstract][Full Text] [Related]
7. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
Delpy E; le Monnier de Gouville AC
Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
[TBL] [Abstract][Full Text] [Related]
9. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Klein T; Eltze M; Grebe T; Hatzelmann A; Kömhoff M
Cardiovasc Res; 2007 Jul; 75(2):390-7. PubMed ID: 17383621
[TBL] [Abstract][Full Text] [Related]
11. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor.
McMahon EG; Palomo MA; Mehta P; Olins GM
J Pharmacol Exp Ther; 1989 Dec; 251(3):1000-5. PubMed ID: 2557409
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
Whalin ME; Scammell JG; Strada SJ; Thompson WJ
Mol Pharmacol; 1991 Jun; 39(6):711-7. PubMed ID: 1646946
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.
Delpy E; Coste H; Gouville AC
Br J Pharmacol; 1996 Oct; 119(3):471-8. PubMed ID: 8894166
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
16. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP.
Wang M; Urenjak J; Fedele E; Obrenovitch TP
Biochem Pharmacol; 2004 Apr; 67(8):1619-27. PubMed ID: 15041479
[TBL] [Abstract][Full Text] [Related]
18. Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition.
Lo YC; Tsou HH; Lin RJ; Wu DC; Wu BN; Lin YT; Chen IJ
Life Sci; 2005 Jan; 76(8):931-44. PubMed ID: 15589969
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium.
Nagata K; Marbán E; Lawrence JH; Donahue JK
J Mol Cell Cardiol; 2001 Mar; 33(3):575-80. PubMed ID: 11181024
[TBL] [Abstract][Full Text] [Related]
20. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
Moreno L; Losada B; Cogolludo Al; Lodi F; Lugnier C; Villamor E; Moro M; Tamargo J; Pérez-Vizcaíno F
Pediatr Res; 2004 Oct; 56(4):563-70. PubMed ID: 15295092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
